Nippon Jibiinkoka Gakkai Kaiho
Online ISSN : 1883-0854
Print ISSN : 0030-6622
ISSN-L : 0030-6622
Volume 107, Issue 5
Displaying 1-4 of 4 articles from this issue
  • Akira Kubota, Madoka Furukawa, Toshiro Kawano, Masanori Komatsu
    2004 Volume 107 Issue 5 Pages 475-482
    Published: May 20, 2004
    Released on J-STAGE: December 15, 2008
    JOURNAL FREE ACCESS
    This study was undertaken to evaluate the clinical efficacy and toxicity of Nedaplatin (254-S) alone or combined for UFT for recurrent head and neck cancers in an outpatient setting. Thirty-two patients, previously treated, (30 men and 2 women, mean age 59 years, twenty one with loco-regional recurrence and 11 with distant metastasis, 29 with squamous cell caricinoma, 2 with adenocarcinoma and one with adenoid cystic carcinoma) were treated with Nedaplatin (254-S) alone or combined with UFF. The primary site was identified in the oropharynx in 8 patients, oral cavity in 7, larynx in 5, nasopharynx in 4, hypopharynx in 3, sinuses in one, parotid in one, and unknown primary in one patient. 254-S was administered at 80 mg/m2 by intravenous drip infusion. The 254 S administration was repeated at 4 week intervals, and in some patients was combined with daily oral administration of 400mg of UFT-E (tegafur-uracil enterogranules). Twelve patients received 254 S alone and in 20 patients it was combined with UFT-E. The 254 S administration ranged from one to 18 course, (mean of 5.7 courses). Grade 3.4 toxicities included leukopenia in 15.6%, anemia in 6.3% and thrombocytopenia in 9.4% of the patients. There was one death due to grade 4 leukopenic pneumonia. Four (12.5%) had a clinical complete and partial response. One-year and two-year overall survival rates were 35.6% and 30.5% for loco-regional recurrence, respectively. Ten of the eleven patients with distant metastasis died within six months and all patients were dead within 18 months, so a significant difference was observed in the overall survival rate between locoregional recurrence and distant metastasis, Treatment with 254 S alone or combined UFT-E could be conducted in an outpatient setting and was able to improve the overall survival rate for recurrent head and neck cancer.
    Download PDF (649K)
  • Yoshiyuki Kawashima, Isako Shibahara, Shino Abe, Hisashi Tokano, Yoshi ...
    2004 Volume 107 Issue 5 Pages 483-488
    Published: May 20, 2004
    Released on J-STAGE: December 15, 2008
    JOURNAL FREE ACCESS
    The aim of this study was to compare the Natus-ALGOR Portable (Portable) device with the Natus-ALGOR 2e and to evaluate its usefulness. Portable, an automated ABR screener (Natus Medical, Foster City, CA, USA) was used to screen 826 neonates in our hospital between February 2002 and March 2003. Tte referral rate for the first automated ABR screening was 0.85% while that for the second Has 0.48%, Hearing impairment was detected in 0.24% of all newborns. The mean duration of the automated ABR test was 2 minutes, 45 seconds. The referral rate and mean test duration of the Portable device was equivalent to that of the Natus-ALGOR 2e. We concluded that the Portable device is a useful tool in view of its low cost and portability.
    Among those who passed the Portable screening, the number of sweeps in the neonatal intensive care unit was significantly greater than that in the maternity ward. Careful estimation of REFER in neonatal intensive care units is important because the incidence of positive fails in the neonatal intensive care unit was much higher than that in the maternity ward. The number of sweeps performed in neonates between the ages of 2 to 6 days was not significantly different.
    Download PDF (1079K)
  • Minako Sato, Kaoru Ogawa, Yasuhiro Inoue, Masatsugu Masuda
    2004 Volume 107 Issue 5 Pages 489-493
    Published: May 20, 2004
    Released on J-STAGE: December 15, 2008
    JOURNAL FREE ACCESS
    We used social and emotional approaches to psychologically evaluate hearing disorders, translating the Hearing Handicap Inventory for Adults (HHIA) into Japanese and using it to evaluate Japanese adults with sensorineural hearing loss The HHIA is a 25-item sell assessment scale composed of 2 subscales, emotional and social/situational, which has been used to evaluate adult patients with hearing disorders in Europe and North America.
    The test-retea reliability of the Japanese version and its screening version (HHIA-S) were excellent (kappa coefficients were 0.912 and 0.812). Due to the limitation of social/situational items, test-retest reliability was only good (0.6<kappa coefficient<0.8), possively because of problems in translating these items.
    We discovered that thee average of scores of the HHIA Japanese version was higher in bilateral hearing disorder patients than in those, with unilateral hearing disorder. This score peaked in 2 to 10 years after onset and decreased thereafter in bilateral hearing disorder patients. The correlation coefficient between the average hearing level of 7 frequencies and scores of the test was highest among the 4 audiological evaluations.
    The HHIA Japanese version is thus useful for following up patients with hearing disorders.
    Download PDF (504K)
  • Kiminori Sato, Tsurumi Hashimoto
    2004 Volume 107 Issue 5 Pages 494-499
    Published: May 20, 2004
    Released on J-STAGE: December 15, 2008
    JOURNAL FREE ACCESS
    Recently, devices which use a new technology that automatically titrates positive airway pressure have become available. Such devices continually adjust the pressure to maintain airway patency. In this paper, unattended automated titration to determine the therapeutic continuous positive airway pressure (CPAP) in patients with obstructive sleep apnea was evaluated to ascertain of it was a feasible titration to determine the therapeutic CPAP.
    Thirty patients participated in this study with obstructive sleep apnea syndrome defined by an apnea hypopnea index >20/h. Automated titration during full polysomnography was performed in the hospital using auto CPAP devices (Autoset T. RESMED Co. Australia). During titration, there was no direct supervision by a technician. The titration method was as follows. Data obtained during the use of auto CPAP devices and polysomnography were used to provide a fixed
    single pressure for subsequent treatment. After determining the therapeutic continuous positive airway pressure, the efficacy of the patient's CPAP device was reconfirmed during full polysomnography.
    The results were, 1) Proper fixed single therapeutic pressure could be determined with this unattended automated titration, consequently apnea and sleep structure could be improved (Total sleep time, Sleep efficiency, %Stage 3+4, Apnea index, Apnea hypopnea index, Arousal index, Lowest SpO2, and Duration of SpO2 less than 90% were improved statistically (p<0.05)). 2) The 95th percentile airway pressure of the auto CPAP device should be applied for the therapeutic pressure. 3) Automated titration during full polysomnography should be performed using auto CPAP devices. 4) After determining the therapeutic CPAP, the efficacy of the patient's CPAI' device should be reconfirmed during full polysomnography. 5) This method of titration was useful at the institution without attendant technician intervention.
    Download PDF (1138K)
feedback
Top